HAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the availability of the HER2Sense™ preclinical imaging agent, to support breast cancer discovery research into personalized medicine. The HER2Sense agent is the first fluorescent, discovery research imaging agent to be based on a commercialized therapeutic antibody.
